These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome. Edgeworth A; Treacy MP; Hurst TP AIDS Rev; 2013; 15(3):171-80. PubMed ID: 24002201 [TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears. Mao Z; Ong AC Nephron Clin Pract; 2009; 112(4):c230-41. PubMed ID: 19546582 [TBL] [Abstract][Full Text] [Related]
8. Glitazones in the treatment of cardiovascular risk factors. Bouhlel MA; Chinetti-Gbaguidi G; Staels B Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():7-13. PubMed ID: 18001313 [TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Giaginis C; Katsamangou E; Tsourouflis G; Zizi-Serbetzoglou D; Kouraklis G; Theocharis S Med Sci Monit; 2009 May; 15(5):BR148-56. PubMed ID: 19396032 [TBL] [Abstract][Full Text] [Related]
10. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair. Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600 [TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451 [TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activating receptors: a new way to treat melanoma? Schadendorf D J Invest Dermatol; 2009 May; 129(5):1061-3. PubMed ID: 19369932 [TBL] [Abstract][Full Text] [Related]
13. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Zieleniak A; Wójcik M; Woźniak LA Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859 [TBL] [Abstract][Full Text] [Related]
14. Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats. Lahiri S; Sen T; Palit G Eur J Pharmacol; 2009 May; 609(1-3):118-25. PubMed ID: 19281808 [TBL] [Abstract][Full Text] [Related]
15. Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid. Yamazaki Y; Kawano Y; Uebayasi M Life Sci; 2008 Jan; 82(5-6):290-300. PubMed ID: 18166202 [TBL] [Abstract][Full Text] [Related]
16. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells. Chung SS; Kim M; Youn BS; Lee NS; Park JW; Lee IK; Lee YS; Kim JB; Cho YM; Lee HK; Park KS Mol Cell Biol; 2009 Jan; 29(1):20-30. PubMed ID: 18936159 [TBL] [Abstract][Full Text] [Related]
17. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079 [TBL] [Abstract][Full Text] [Related]
18. Activation of peroxisome proliferator-activated receptor-gamma potentiates pro-inflammatory cytokine production, and adrenal and somatotropic changes of weaned pigs after Escherichia coli lipopolysaccharide challenge. Liu Y; Shi J; Lu J; Meng G; Zhu H; Hou Y; Yin Y; Zhao S; Ding B Innate Immun; 2009 Jun; 15(3):169-78. PubMed ID: 19474210 [TBL] [Abstract][Full Text] [Related]
19. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma. Li X; Yang X; Xu Y; Jiang X; Li X; Nan F; Tang H Cell Res; 2009 Jun; 19(6):720-32. PubMed ID: 19417774 [TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes. Liu J; Xia Q; Zhang Q; Li H; Zhang J; Li A; Xiu R Shock; 2009 Sep; 32(3):317-24. PubMed ID: 19174742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]